Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereinafter referred to as Biocytogen) is an international biotechnology company driven by innovative technologies for new drug development. With a mission focused on technological innovation, continuous production of new drugs, and safeguarding human health, the company is committed to becoming a global source of new drug discovery. At the core of Biocytogen's operations are its proprietary and fully independently owned intellectual property rights for the fully human antibody platforms RenMab®, RenLite®, and RenNano® mice. The company integrates a high-throughput single-cell antibody discovery platform, an efficient gene-editing model development platform, a large-scale animal model supply platform, a rapid in vivo and in vitro drug efficacy evaluation platform, and strong clinical development capabilities to form a distinctive new drug research and development system covering the entire drug R&D process. Biocytogen actively promotes both independent and collaborative new drug development. Currently, several self-developed antibody drugs have entered clinical trials. With the implementation of the large-scale antibody drug development initiative - the "Project 1000 Mice & 10,000 Antibodies," the company will further focus on new drug R&D. In the future, Biocytogen will work with global partners to accelerate the new drug development process. Biocytogen's headquarters is located in Beijing, with branches in Haimen, Jiangsu; Boston, USA; Shanghai, and other locations. Its wholly-owned subsidiary, Youhe Medicine, focuses on clinical development.